Sunitinib as an anti-endometriotic agent

Manal A Abbas, Ahmad M Disi, Mutasem O Taha
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2013 · vol. 49(4) , pp. 732–736 · doi:10.1016/j.ejps.2013.05.021 · PMID:23747661 · W2021667437
article OA: closed CC0 ⤵ 15 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Sunitinib, a receptor tyrosine kinase inhibitor, demonstrated anti-endometriotic effects by reducing lesion size and inhibiting angiogenesis in a preclinical model.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

mesh:D004715

MeSH descriptors

Endometriosis Protein Kinase Inhibitors Animals Apoptosis Apoptosis Endometriosis Endometriosis Endometrium Endometrium Epithelial Cells Epithelial Cells Epithelial Cells Female Indoles Indoles In Situ Nick-End Labeling Protein Kinase Inhibitors Pyrroles Pyrroles Rats

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (28)

Cited by (15)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:18:59.468224+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK